Corrigendum to "Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: An European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874)" [European Journal of Cancer, 44 (2008) 808-818] (DOI:10.1016/j.ejca.2008.01.019);Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: An European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874)

European Journal of Cancer

Volumn 44, Issue 6, 2008, Pages 808-818

  Reed, N S ^a   Mangioni, C ^b   Malmstrom H ^c   Scarfone, G ^c   Poveda, A ^c   Pecorelli, S ^c   Tateo, S ^c   Franchi, M ^c   Jobsen, J J ^c   Coens, C ^d   Teodorovic, I ^d   Vergote, I ^c   Vermorken, J B ^c  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^b SAN GERARDO HOSPITAL   (Italy)

^c EORTC Data Centre ^*

^d EORTC Data Centre   (Belgium)

Author keywords

Adjuvant; EORTC; Gynaecological; Phase 3; Radiotherapy; Randomised clinical trial; Uterine sarcomas

Indexed keywords

ABDOMINAL HYSTERECTOMY; ADULT; AGED; ARTICLE; BEAM THERAPY; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; CARCINOSARCOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENDOMETRIUM SARCOMA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PERITONEUM LAVAGE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; SALPINGOOOPHORECTOMY; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; UTERUS SARCOMA;

EID: 41849100978     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.01.029     Document Type: Erratum

References (40)

1. Edwards C.L. Undifferentiated tumours. Cancer of uterus and ovary year book (1969), Medical Publishers Inc., Chicago p. 84-94
2. Badib A.O., Vongtama V., Kurohara S.S., and Webster J.H. Radiotherapy in the treatment of sarcomas of the corpus uteri. Cancer 24 (1969) 724-729
3. Belgrad R., Elbadawi N., and Rubin P. Uterine sarcoma. Radiology 144 1 (1975) 181-188
4. Salazar O., Bonfiglio T.K., Patten S.F., et al. Uterine sarcomas: natural history, treatment and prognosis. Cancer 42 (1978) 1152-1160
5. Hornback N.B., Omura G., and Major F.J. Observations on the use of adjuvant radiation therapy in patients with stage I and II uterine sarcoma. Int J Radiat Oncol Biol Phys 12 12 (1986) 2127-2130
6. Le T. Adjuvant pelvic radiotherapy for uterine carcinosarcoma in a high risk population. Eur J Surg Oncol 27 3 (2001) 282-285
7. Chauveinc L., Deniaud E., Plancher C., et al. Uterine sarcomas: the Curie Institute experience. Prognosis factors and adjuvant treatments. Gynecol Oncol 72 2 (1999) 232-237
8. George M., Pejovic M.H., Kramar A., and Gynecologic Cooperating Group of French Oncology Centers. Uterine sarcomas: prognostic factors and treatment modalities-study on 209 patients. Gynecol Oncol 24 (1986) 58-67
9. Sorbe B. Radiotherapy and/or chemotherapy as adjuvant treatment of uterine sarcomas. Gynecol Oncol 20 (1985) 281-289
10. Rose P.G., Piver M.S., Tsukada Y., and Lau T. Patterns of metastasis in uterine sarcoma. An autopsy study. Cancer 63 (1989) 935-938
11. Omura G.A., Blessing F.J., Sedlacek J.A., Thigpen J.T., Creasman W.T., and Zaino R.J. A randomised trial of Adriamycin with and without dimethyltrainoimidazole carboxamide in advanced uterine sarcomas. Cancer 52 (1983) 626-632
12. Tierney J.F., Mosseri V., Stewart L.A., Souhami R.L., and Parmar M.K. Adjuvant chemotherapy for soft-tissue sarcoma: review and meta-analysis of the published results of randomised clinical trials. Br J Cancer 72 2 (1995) 469-475
13. Bramwell V.H. Adjuvant chemotherapy for adult soft tissue sarcoma: is there a standard of care?. J Clin Oncol 19 5 (2001) 1238-1247
14. Wolfson AH, Brady MF, Rocereto TF, et al. A Gynecologic Oncology Group randomized trial of whole abdominal irradiation (WAI) vs. cisplatin, ifosfamide and mesna (CIM) in optimally debulked stage 1-1V carcinosarcoma (CS) of the uterus. Proc Am Soc Clin Oncol 2006 [abstract 5001].
15. McCluggage W.G. Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas?. J Clin Pathol 55 5 (2002) 460-469
16. Zelmanowicz A., Hildesheim A., Sherman M.E., et al. Evidence for a common aetiology for endometrial carcinomas and malignant mixed Mullerian tumours. Gynecol Oncol 69 (1998) 253-257
17. Amant F., and Vergote I. Bifunctional pathway of uterine carcinosarcomas. Hum Pathol 34 3 (2003) 299
18. Amant F., Dreyer L., Makin J., Vergote I., and Lindeque B.G. Uterine sarcomas in South African black women: a clinicopathologic study with ethnic considerations. Eur J Gynaecol Oncol 22 3 (2001) 194-200
19. Sreenan J.J., and Hart W. Carcinosarcomas of the female genital tract. A pathologic study of 29 metastatic tumors; further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis. Am J Surg Pathol 5 (1995) 310-313
20. Amant F., Cadron I., Fuso L., et al. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high risk epithelial endometrial cancer. Gynecol Oncol 98 (2005) 274-280
21. Creutzfeld C., Putten W.L., Koper P.C., et al. Surgery and post-operative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial: PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma. Lancet 355 (2000) 1404-1411
22. Keys H.M., Roberts J.A., Brunetto V.L., et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92 (2004) 744-751
23. ICRU. ICRU 29, Dose specification for reporting external beam therapy with photons and electrons, Report 29, USA, Bethesda; 1978.
24. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
25. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50 (1966) 163-170
26. Fleiss J.L. Statistical methods for ratio and proportions. The measurement of interrater agreement. 2nd ed. (1981), John Wiley, New York p. 212-36 [chapter 13]
27. Gray R.J. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Annal Stat 16 (1988) 1141-1154
28. O'Brien P.C., and Fleming T.R. A multiple testing procedure for clinical trials. Biometrics 35 (1979) 549-556
29. Major F.J., Blessing J.A., Silverberg S.G., et al. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer 71 (1993) 1702-1709
30. Giuntoli II R.L., Metzinger D.S., DiMarco C.S., et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management and adjuvant therapy. Gynecol Oncol 89 (2003) 460-469
31. Manolitsas T.P., Wain G.V., Williams K.E., et al. Multimodality therapy for patients with clinical stage I and II malignant mixed Mullerian tumors of the uterus. Cancer 91 (2001) 1437-1443
32. Dusenberry K.E., Potish R.A., and Judson P. Limitations of adjuvant radiotherapy for uterine sarcomas spread beyond the uterus. Gynecol Oncol 94 (2004) 191-196
33. Randall M.E., Filiaci V.L., Muss H., et al. Randomized Phase III Trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 24 1 (2006) 36-44
34. Brooks S.E., Zhan M., Cote T., and Baquet C. Surveillance, epidemiology and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol Oncol 93 (2004) 204-208
35. Menczer J., Levy T., Piura B., et al. A comparison between different post operative treatment modalities of uterine carcinosarcoma. Gynecol Oncol 97 (2005) 166-170
36. Gerszten K., Faul C., Kounelis S., et al. The impact of adjuvant radiotherapy on carcinosarcoma of the uterus. Gynecol Oncol 68 (1998) 8-13
37. Gadducci A., Sartori E., Landoni F., et al. The prognostic relevance of histological type in uterine sarcomas: a Cooperation Task Force (CTF) multivariate analysis of 249 cases. Eur J Gynaecol Oncol 23 4 (2002) 295-299
38. . Gynaecological Cancer Inter Group.
39. Sutton G., Kauderer J., Carson L.F., Lentz S.S., Whitney C.W., and Gallion H. Gynecologic Oncology Group Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 96 3 (2005) 630-634
40. Hogberg T, Rosenberg P, Kristensen G, et al. A randomized phase-III study on adjuvant treatment with radiation (RT) ± chemotherapy (CT) in early-stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991). Proc Am Soc Clin Oncol 2007 [abstract 5503].